• Home
  • HCN Trends
  • Contact Us

Search Articles

Cardiology Covid-19 Dermatology Endocrinology General Interest Hematology Infectious Disease Neurology Oncology Pediatrics Psychiatry Pulmonology Rheumatology Surgery Uncategorized
acetaminophen actemra adverse events anemia antibody anxiety azithromycin bipolar disorder bleeding blog brain tumor breast cancer burnout Cancer capecitabine capmatinib cervical cancer chloroquine chronic pain clinical trials cloroquine CME compensation coronary artery disease coronavirus cost covid-19 death diagnosis doctors dosing drug interactions efficacy erlotinib exercise FDA/regulation fever filters glioblastoma green tea guidelines hemophilia hiv hospital hydroxychloroquine ibrutinib ibuprofen immunity induction chemotherapy infectious disease influenza ipilimumab irinotecan iron-deficiency anemia isn letrozole leukemia Lung cancer malaria mask Masks mbc MDS medical cannabis medical school Medicine mesothelioma metastatic colorectal cancer Myelodysplastic Syndromes myeloid leukemia nivolumab nsclc olaparib osimertinib outcomes pandemic patient safety patients pediatrics perjeta physicians podcast practice practice management prevention procedure prostate cancer radiation remdesivir research/studies respirators respiratory retevmo rucaparib sars SCLC selinexor selpercatinib sorafenib stroke Survival/Mortality symptoms syndrome telemedicine testing therapy thrombosis thyroid cancer time tnbc tocilizumab trastuzumab treatment vaccine venetoclax xpovio

Tag: nsclc

Haymarket MediaALK-Rearranged NSCLC Linked to Higher Venous and Arterial Thrombotic Risk

The findings, recently published in the Journal of Thoracic Oncology, suggested that patients with ALK rearrangements may benefit from prophylactic anticoagulation, and venous thromboembolism risk prediction scores may improve if ALK rearrangement status is incorporated.

nsclcCancerpatients

Haymarket MediaFoundationOne CDx Approved as Companion Diagnostic for Capmatinib for METex14 NSCLC

The approval of capmatinib and its companion diagnostic is the first of its kind for this specific diagnosis, using next-generation sequencing to perform comprehensive genomic profiling of solid tumors. It now has FDA approval for 21 different agents.

Cancercapmatinibnsclc
  • © Healthcare Communications Network
  • Privacy Policy